Platelet dose for prophylactic platelet transfusions

Expert Review of Hematology

Volumn 3, Issue 4, 2010, Pages 397-400

  Cid, Joan ^a   Lozano, Miguel ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

hemorrhage; platelet dose; platelet transfusion

Indexed keywords

ARTICLE; BLOOD TRANSFUSION REACTION; CLINICAL FEATURE; CLINICAL TRIAL; ERYTHROCYTE TRANSFUSION; HUMAN; HYPOPROLIFERATIVE THROMBOCYTOPENIA; PRIORITY JOURNAL; PROPHYLAXIS; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 77955592101     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.10.36     Document Type: Article

References (29)

1. Heal JM, Blumberg N. Optimizing platelet transfusion therapy. Blood Rev. 18, 149-165 (2004).
2. Guidelines for the use of platelet transfusions. Br. J. Haematol. 122, 10-23 (2003).
3. Tinmouth AT, Freedman J. Prophylactic platelet transfusions: which dose is the best dose? A review of the literature. Transfus. Med. Rev. 17, 181-193 (2003).
4. Heddle NM, Cook RJ, Tinmouth A et al. A randomized controlled trial comparing standard and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood 113, 1564-1573 (2009).
5. Slichter SJ, Kaufman RM, Assmann SF et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N. Engl. J. Med. 362, 600-613 (2010).
6. Stanworth SJ, Dyer C, Casbard A, Murphy MF. Feasibility and usefulness of self-assessment of bleeding in patients with haematological malignancies, and the association between platelet count and bleeding. Vox Sang. 91, 63-69 (2006).
7. van Rhenen D, Gulliksson H, Cazenave JP et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 101, 2426-2433 (2003).
8. McCullough J, Vesole DH, Benjamin RJ et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 104, 1534-1541 (2004).
9. Cook RJ, Heddle NM, Rebulla P, Sigouin CS, Webert KE. Methods for the analysis of bleeding outcomes in randomized trials of PLT transfusion triggers. Transfusion 44, 1135-1142 (2004).
10. Klumpp TR, Herman JH, Gaughan JP et al. Clinical consequences of alterations in platelet transfusion dose: a prospective, randomized, double-blind trial. Transfusion 39, 674-681 (1999).
11. Norol F, Bierling P, Roudot-Thoraval F et al. Platelet transfusion: a dose-response study. Blood 92, 1448-1453 (1998).
12. Roy AJ, Jaffe N, Djerassi I. Prophylactic platelet transfusions in children with acute leukemia: a dose response study. Transfusion 13, 283-290 (1973).
13. Goodnough LT, Kuter DJ, McCullough J et al. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. Blood 98, 1346-1351 (2001).
14. Tinmouth A, Tannock IF, Crump M et al. Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design. Transfusion 44, 1711-1719 (2004).
15. Sensebe L, Giraudeau B, Bardiaux L et al. The efficiency of transfusing high doses of platelets in hematologic patients with thrombocytopenia: results of a prospective, randomized, open, blinded end point (PROBE) study. Blood 105, 862-864 (2005).
16. Cid J, Lozano M. Lower or higher doses for prophylactic platelet transfusions: results of a meta-analysis of randomized controlled trials. Transfusion 47, 464-470 (2007).
17. Konkle BA, Nemo GJ. Defining effective therapies in transfusion medicine and hemostasis: new opportunities with the TMH Network. Transfusion 45, 1404-1406 (2005).
18. Slichter SJ. Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients. J. Clin. Apher. 21, 78-84 (2006).
19. Cid J, Lozano M, Escolar G. ABO compatibility in platelet transfusion. N. Engl. J. Med. 362, 2140 (2010).
20. Lozano M, Cid J. The clinical implications of platelet transfusions associated with ABO or Rh(D) incompatibility. Transfus. Med. Rev. 17, 57-68 (2003).
21. Heal JM, Masel D, Rowe JM, Blumberg N. Circulating immune complexes involving the ABO system after platelet transfusion. Br. J. Haematol. 85, 566-572 (1993).
22. Slichter SJ, Davis K, Enright H et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 105, 4106-4114 (2005).
23. Lozano M, Heddle NM, Williamson LM, Wang G, AuBuchon JP, Dumont LJ. Practices associated with ABO-incompatible platelet transfusions: a BEST collaborative international survey. Transfusion (2010) (In press).
24. Heddle NM, Cook RJ, Webert KE, Sigouin C, Rebulla P. Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion 43, 742-752 (2003).
25. Wandt H, Schaefer-Eckart K, Frank M, Birkmann J, Wilhelm M. A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 37, 387-392 (2006).
26. Avvisati G, ten Cate JW, Buller HR, Mandelli F. Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet 2, 122-124 (1989).
27. Ben-Bassat I, Douer D, Ramot B. Tranexamic acid therapy in acute myeloid leukemia: possible reduction of platelet transfusions. Eur. J. Haematol. 45, 86-89 (1990).
28. Shpilberg O, Blumenthal R, Sofer O et al. A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. Leuk. Lymph. 19, 141-144 (1995).
29. Fricke W, Alling D, Kimball J, Griffith P, Klein H. Lack of efficacy of tranexamic acid in thrombocytopenic bleeding. Transfusion 31, 345-348 (1991).